Laura K. Shawver

Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant

B Millauer, Laura K. Shawver, Karl H. Plate et al. · Nature · 1994 · 1.2K citations

Medicine, Cancer Biology, Oncology +12

SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.

T. Annie T. Fong, Laura K. Shawver, Li Sun et al. · PubMed · 1999 · 1K citations

Medicine, Oncology, Pharmacology +16

SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.

Alexander Laird, Peter Vajkoczy, Laura K. Shawver et al. · PubMed · 2000 · 497 citations

Medicine, Medicinal Chemistry, Pharmacology +16

Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis

Daniel J. Anderson, Ronan Le Moigne, Stevan Djakovic et al. · Cancer Cell · 2015 · 401 citations · Full text

Life Sciences, Molecular Biology, Oncology +8

Design, Synthesis, and Evaluations of Substituted 3-[(3- or 4-Carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as Inhibitors of VEGF, FGF, and PDGF Receptor Tyrosine Kinases

Li Sun, Ngoc Quang Tran, Congxin Liang et al. · Journal of Medicinal Chemistry · 1999 · 272 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17